ONC Earnings Prediction
The chart below shows how ONC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ONC sees a -18.80% change in stock price 10 days leading up to the earnings, and a +0.00% change 10 days following the report. On the earnings day itself, the stock moves by +6.18%. This data can give you a slight idea of what to expect for the next quarter's release.
ONC Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
ONC Earnings Analysis
Beigene Ltd Corporation (ONC.O) Earnings Conference Call
Positive
Revenue Surge in 2024: 2024 was a remarkable year with $3.8 billion in revenue, a 55% increase from 2023, and $1.1 billion in Q4 alone.
Record Revenue Growth: BRUKINSA U.S. revenue exceeded $800 million in Q4, marking a 100% growth compared to Q4 2023, and solidifying its position as the BTK class leader.
R&D Productivity Boost: The company introduced 13 new molecular entities into the clinic in 2024, showcasing strong R&D productivity.
Market Leadership in CLL: BRUKINSA has become the BTK inhibitor of choice, with over 50% new patient share in CLL, and is close to overtaking IMBRUVICA in revenue.
Positive Cash Flow Achievement: The company achieved positive cash flow from operations for the third consecutive quarter, indicating strong financial health.
Gross Margin Improvement: BeiGene's gross margin improved to 85.6% in Q4, reflecting favorable sales mix and cost efficiencies.
Strong Financial Position: The company has a strong balance sheet with $2.6 billion in cash, positioning it well for future growth and sustainability.
2025 Revenue Projections: Projected revenue for 2025 is between $4.9 billion to $5.3 billion, indicating continued growth and market expansion.
Negative
Market Competition Challenges: BRUKINSA's growth is impressive, but it is still in a highly competitive market with established players like IMBRUVICA and Calquence, which may limit future market share gains.
Profitability Challenges Despite Revenue: Despite achieving $3.8 billion in revenue, the company faces challenges in maintaining profitability, as indicated by the significant operating expenses totaling $1 billion in Q4.
Revenue Dependence on BRUKINSA: The company is heavily reliant on BRUKINSA for revenue, with 55% of total revenues in Q4 coming from the U.S. market, indicating a lack of diversification in revenue streams.
Competitive Treatment Landscape: The fixed duration treatment landscape is competitive, and current options have shown underwhelming efficacy, which may hinder the company's ability to capture market share in this segment.
Rising Clinical Trial Costs: The company has acknowledged that clinical trials are becoming increasingly expensive, with costs rising to $250,000 to $300,000 per patient, which could impact future R&D investments and returns.
Projected Operating Expenses: Operating expenses are projected to be between $4.1 billion and $4.4 billion, which may strain the company's financial resources as it aims for profitability in 2025.
ONC FAQs
How does ONC typically perform around its earnings report dates?
Is Beigene Ltd (ONC) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ONC Earning Call Sentiment
BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript
ONC.O
6.18%Positive
The earnings call summary indicates strong revenue growth, significant product development, and promising guidance for 2025. Despite competitive pressures, the company is optimistic about its market position, especially with BRUKINSA. The Q&A section reveals positive sentiment from analysts regarding revenue growth and product efficacy, although some concerns about management's clarity on timelines exist. The lack of a share repurchase program is a minor negative, but overall, the strong financial performance and optimistic guidance outweigh the risks, suggesting a positive stock price reaction.
